Accéder au contenu
Merck
Toutes les photos(1)

Documents

R0700000

Rifampicine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

3-(4-méthylpipérazinyliminométhyl)rifamycine SV, Rifampine, Rifamycine AMP

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C43H58N4O12
Numéro CAS:
13292-46-1
Poids moléculaire :
822.94
Numéro Beilstein :
5723476
Numéro MDL:
MFCD00151389
Code UNSPSC :
41116107
ID de substance PubChem :
329823991
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

rifampicin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O

InChI

1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

Clé InChI

JQXXHWHPUNPDRT-WLSIYKJHSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Rifampicin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Inhibe l'assemblage de l'ADN et de la protéine en particules virales matures.
Mode d'action : inhibe l'initiation de la synthèse de l'ARN en se liant à la sous-unité β de l'ARN polymérase.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Isoniazid Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1932

Isoniazid

Rifamycin Sodium Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1664

Rifamycin Sodium

Isoniazid analytical standard, ≥99% (TLC)

Supelco

I3377

Isoniazid

Pyrazinamide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1576

Pyrazinamide

Pyrazinamide United States Pharmacopeia (USP) Reference Standard

USP

1585006

Pyrazinamide

Pyrazinamide British Pharmacopoeia (BP) Reference Standard

BP906

Pyrazinamide

Leonardo Acuña et al.
Cells, 8(8) (2019-07-28)
: Aggregated forms of the synaptic protein α-synuclein (αS) have been proposed to operate as a molecular trigger for microglial inflammatory processes and neurodegeneration in Parkinson´s disease. Here, we used brain microglial cell cultures activated by fibrillary forms of recombinant
Stephen D Lawn et al.
Future microbiology, 6(9), 1067-1082 (2011-10-01)
Global TB control efforts have been severely hampered by the lack of diagnostic tests that are accurate, simple to use and can be applied at the point of clinical care. This has been further compounded by the widespread inability to
S Harbarth et al.
The Journal of antimicrobial chemotherapy, 70(1), 264-272 (2014-09-12)
The therapeutic arsenal for MRSA infections is limited. The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection. We conducted a randomized, open-label, single-centre
J Minion et al.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 14(8), 941-951 (2010-07-16)
To update a previously reported meta-analysis of evidence regarding the diagnostic accuracy and performance characteristics of commercial and non-commercial phage-based assays for the detection of rifampicin (RMP) resistant tuberculosis (TB). DESIGN AND OUTCOMES: We conducted a systematic review and meta-analysis
Karen R Steingart et al.
The Cochrane database of systematic reviews, 1(1), CD009593-CD009593 (2013-02-27)
Accurate and rapid detection of tuberculosis (TB) and drug resistance are critical for improving patient care and decreasing the spread of TB. Xpert® MTB/RIF assay (Xpert) is a rapid, automated test that can detect both TB and rifampicin resistance, within
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique